Reshma Kewalramani Age, Husband, Children, Biography

Bio/Wiki
Profession	President and CEO of Vertex Pharmaceuticals
Known For	Being the first female CEO of a large US biotech company
Physical Stats
Eye Colour	Brown
Hair Colour	Brown
Career
Board Member	• Boston University School of Medicine • Massachusetts General Hospital • Kidney Health Initiative (KHI) • Biomedical Science Careers Program (BSCP)
Awards	• Harvard Medical School Excellence in Teaching Award • International Institute of New England Golden Door Award • New England Council New Englander of the Year • Fortune Most Powerful Women List
Personal Life
Date of Birth	Year, 1973
Age (as of 2025)	52 Years
Birthplace	Mumbai, Maharashtra, India
Nationality	Indian
Hometown	Huntington, New York, United States
College/University	• Boston University (1990-1998) • Harvard Business School (2015)
Educational Qualification(s)	• Doctor of Medicine (MD), Seven-year Liberal Arts/Medical Education Program from Boston University School of Medicine • General Management Program from Harvard Business School
Social Media	• Facebook • LinkedIn
Relationships & More
Marital Status	Married
Family
Husband/Spouse
Children	Son(s)- 2 (twins) Daughter- None
Money Factor
Net Worth (approx.)	$100 million (as of 2025)

Some Lesser Known Facts About Reshma Kewalramani

• Reshma Kewalramani moved from Mumbai, India, to the United States with her family when she was 11.

• Reshma worked as a Resident Physician at Massachusetts General Hospital in the Greater Boston Area from 1998 to 2001.

• She served as a Nephrology Fellow at Partners HealthCare in the Greater Boston Area from 2001 to 2002.

• Reshma worked as a Nephrologist and Research Fellow at Brigham and Women’s Hospital in the Greater Boston Area from 2002 to 2004.

• Reshma began working at Amgen in August 2004, where she spent over six years in different positions within Global Clinical Development and Medical Affairs in Thousand Oaks, California.

• Reshma became Vice President and Head of the Nephrology and Metabolic Therapeutic Area in Global Clinical Development at Amgen, where she worked from October 2010 to June 2014 in Thousand Oaks.

• Reshma served as Vice President and Head of the US Medical Organisation at Amgen in Thousand Oaks from June 2014 to January 2017.

• In February 2017, Reshma Kewalramani joined Vertex Pharmaceuticals as Senior Vice President in Boston and served in this position until April 2018.

• She served as Executive Vice President and Chief Medical Officer at Vertex Pharmaceuticals in Boston from April 2018 to April 2020.

• Reshma was appointed as the CEO and President at Vertex Pharmaceuticals in April 2020. She also served as a member of the Vertex Board of Directors.

• After taking over as CEO, Kewalramani helped Vertex expand its cystic fibrosis portfolio with new approvals like Trikafta and Alyftrek.

• At Vertex, Kewalramani led efforts in gene editing and cell therapy. Under her guidance, Casgevy got approved in 2023, and the team continued exploring treatments for type 1 diabetes.

• In 2025, Kewalramani led Vertex to a breakthrough with the FDA approval of Journavx (suzetrigine), the first new class of pain medicine in more than 20 years.

• Reshma Kewalramani is an avid animal lover and has a pet dog named Snickers.
  

  Reshma Kewalramani with her pet dog, Snickers

• She believes in giving back to society and plays an active role in Vertex Volunteers, supporting nonprofit work globally.
  

  Reshma Kewalramani, as part of Vertex Volunteers